A late-breaking study at Heart Rhythm 2016 finds complication rates to be significantly lower in the LEADLESS II trial of a leadless pacemaker than in real-world use of transvenous pacing devices.
The year just passed was full of insights and innovations likely to be felt for many years to come. Here are 15 such developments in which Cleveland Clinic staff played key roles.
Interim results from a major study of a leadless pacemaker show good safety and efficacy, echoing a recent trial of a similar device. Here’s how these devices may shape the future of cardiac pacing.
Data presented at the European Society of Cardiology meeting give a boost to leadless pacemaking technology, which a Cleveland Clinic co-investigator calls “a big leap forward.”
Current Cleveland Clinic heart and vascular studies include two on leadless pacemakers, one on evolocumab for statin intolerance and one on gut flora reduction after dietary intervention.
Five new technologies — subcutaneous ICDs, contact force ablation catheters, leadless pacemakers, a vagal nerve stimulator and a left atrial appendage occlusion device — are making EP procedures safer and more effective.
At one-tenth the size of their traditional counterparts, leadless pacemakers hold the promise of fewer infections, dislodgements and failures. U.S. studies are underway to put that promise to the test.